Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Autoimmune Disorders

  Free Subscription


1 Acta Neurol Scand
1 Brain
1 Diabetes
5 J Neurol
2 J Rheumatol
2 Mult Scler
1 Nat Rev Neurol
1 Neurologia (Engl Ed)
3 PLoS One
1 Thyroid

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Acta Neurol Scand

  1. HAYAT S, Asad A, Hasan I, Jahan I, et al
    Nucleotide oligomerization domain polymorphism confers no risk to Guillain-Barre syndrome.
    Acta Neurol Scand. 2022 Jun 2. doi: 10.1111/ane.13649.
    PubMed         Abstract available


  2. MADSEN MAJ, Wiggermann V, Marques MFM, Lundell H, et al
    Linking lesions in sensorimotor cortex to contralateral hand function in multiple sclerosis: a 7 T MRI study.
    Brain. 2022 Jun 2. pii: 6599027. doi: 10.1093.
    PubMed         Abstract available


  3. LIN Y, Perovanovic J, Kong Y, Igyarto BZ, et al
    Antibody-Mediated Targeting of a Hybrid-Insulin-Peptide Towards Neonatal Thymic Langerin+ Cells Enhances T Cell Central Tolerance and Delays Autoimmune Diabetes.
    Diabetes. 2022 May 27. pii: 147050. doi: 10.2337/db21-1069.
    PubMed         Abstract available

    J Neurol

  4. DORCET G, Migne H, Biotti D, Bost C, et al
    Early B cells repopulation in multiple sclerosis patients treated with rituximab is not predictive of a risk of relapse or clinical progression.
    J Neurol. 2022 Jun 2. pii: 10.1007/s00415-022-11197.
    PubMed         Abstract available

  5. MISCIOSCIA A, Puthenparampil M, Miante S, Pengo M, et al
    Retinal inner nuclear layer thinning is decreased and associates with the clinical outcome in ocrelizumab-treated primary progressive multiple sclerosis.
    J Neurol. 2022 Jun 1. pii: 10.1007/s00415-022-11183.
    PubMed         Abstract available

  6. HRASTELJ J, Robertson NP
    A role for the Epstein-Barr virus in multiple sclerosis aetiology?
    J Neurol. 2022 May 31. pii: 10.1007/s00415-022-11177.

  7. GOLD R, Piani-Meier D, Kappos L, Bar-Or A, et al
    Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study.
    J Neurol. 2022 May 31. pii: 10.1007/s00415-022-11166.
    PubMed         Abstract available

  8. JARIUS S, Komorowski L, Regula JU, Haas J, et al
    Rho GTPase-activating protein 10 (ARHGAP10/GRAF2) is a novel autoantibody target in patients with autoimmune encephalitis.
    J Neurol. 2022 May 27. pii: 10.1007/s00415-022-11178.
    PubMed         Abstract available

    J Rheumatol

  9. ROSS C, Elfassy HL, Makhzoum JP
    Somatic Mutation in UBA1 and ANCA-associated Vasculitis.
    J Rheumatol. 2021;48:1626-1627.

  10. SIMONS G, Falahee M
    Fear of the Unknown: Can We Help Individuals With a Systemic Autoimmune Rheumatic Disease Deal With Uncertainty?
    J Rheumatol. 2022 Jun 1. pii: jrheum.220502. doi: 10.3899/jrheum.220502.
    PubMed         Abstract available

    Mult Scler

  11. BEREK K, Hegen H, Hocher J, Auer M, et al
    Retinal layer thinning as a biomarker of long-term disability progression in multiple sclerosis.
    Mult Scler. 2022 Jun 2:13524585221097566. doi: 10.1177/13524585221097566.
    PubMed         Abstract available

  12. KANINIA S, Grammatikos A, Urankar K, Renowden SA, et al
    CNS demyelination associated with immune dysregulation and a novel CTLA-4 variant.
    Mult Scler. 2021;27:1464-1467.
    PubMed         Abstract available

    Nat Rev Neurol

  13. FYFE I
    Ageing reduces potential for remyelination in multiple sclerosis.
    Nat Rev Neurol. 2022 May 31. pii: 10.1038/s41582-022-00680.

    Neurologia (Engl Ed)

  14. DIAZ-MAROTO I, Garcia-Garcia J, Sanchez-Ayaso PA, Alcahut-Rodriguez C, et al
    Ocular myasthenia gravis and risk factors for developing a secondary generalisation: description of a Spanish series.
    Neurologia (Engl Ed). 2022 May 27. pii: S2173-5808(22)00053.
    PubMed         Abstract available

    PLoS One

  15. COYNE MJ, Schultze AE, McCrann DJ 3rd, Murphy RE, et al
    Evaluation of renal injury and function biomarkers, including symmetric dimethylarginine (SDMA), in the rat passive Heymann nephritis (PHN) model.
    PLoS One. 2022;17:e0269085.
    PubMed         Abstract available

  16. ELKHALII-WILHELM S, Sippel A, Riemann-Lorenz K, Kofahl C, et al
    Experiences of persons with Multiple Sclerosis with lifestyle adjustment-A qualitative interview study.
    PLoS One. 2022;17:e0268988.
    PubMed         Abstract available

  17. KOFFMAN J, Penfold C, Cottrell L, Farsides B, et al
    "I wanna live and not think about the future" what place for advance care planning for people living with severe multiple sclerosis and their families? A qualitative study.
    PLoS One. 2022;17:e0265861.
    PubMed         Abstract available


  18. HOU X, Guan H, Sun S, Shi Y, et al
    Outcomes of Early-pregnancy Antithyroid Drug Withdrawal in Graves' Disease: A Preliminary Prospective Follow-up Study.
    Thyroid. 2022 Jun 1. doi: 10.1089/thy.2022.0088.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Autoimmune Disorders is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.